SummerHaven Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

SummerHaven Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-33,123	Closed	-$958K	–	264
2022 Q2	$958K	Hold	33,123	–	–	0.65%	43
2022 Q1	$1.07M	Buy	33,123 +1,505	+5%	+$46.1K	0.6%	46
2021 Q4	$922K	Hold	31,618	–	–	0.5%	89
2021 Q3	$843K	Buy	31,618 +13,353	+73%	+$358K	0.49%	100
2021 Q2	$562K	Buy	18,265 +459	+3%	+$14.1K	0.32%	172
2021 Q1	$466K	Hold	17,806	–	–	0.28%	194
2020 Q4	$448K	Buy	+17,806	New	+$383K	0.35%	189

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SummerHaven Investment Management's SUPN Position: Q3 2022 in Review

SummerHaven Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2022, closing a stake of 33,123 shares — an estimated $958K sold.

SummerHaven Investment Management first reported a position in SUPN in Q4 2020 and held it in 7 quarters. The position peaked at $1.07M in Q1 2022. 244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

SummerHaven Investment Management reported no remaining Supernus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
SummerHaven Investment Management sold 33,123 Supernus Pharmaceuticals shares in Q3 2022, an estimated $958K.
SummerHaven Investment Management first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 7 quarters.
SummerHaven Investment Management's Supernus Pharmaceuticals position peaked at $1.07M in Q1 2022.
244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on SummerHaven Investment Management's 13F filing for Q3 2022, filed 20 Oct 2022.